Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 20

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 20
---
 decline and delay the development of our product candidates. Pending our use to fund operations, we may invest our cash, cash equivalents and marketable securities in a manner that does not produce income or that loses value. 8 Table of Contents Risks Related to Research and Development and the Biopharmaceutical Industry Preliminary, top-line or interim data from our clinical trials that we announce or publish from time to time may change as more data become available, and are subject to audit and verification procedures that could result in material changes in the final results or could otherwise harm our business, financial condition, results of operation and prospects. From time to time we have, and in the future may continue to, publicly disclose preliminary, top-line, or interim data from our clinical trials, which is based on an analysis of then-available data. For example, on February 3, 2025, we announced efficacy data from such phase relating to our ongoing open-label extension phase of our randomized, double-blind, placebo-controlled Phase 2b trial for GH001 in TRD (GH001-TRD-201), as of January 22, 2025, and which did not include data relating to the safety profile for GH001 in TRD (GH001-TRD-201). However, the open-label extension phase of this trial is not yet complete, including our safety analysis for such phase. Consequently, ultimate results could differ materially from the data we have announced. In addition, because we have not completed a safety analysis, notwithstanding efficacy results for the open-label extension phase of our randomized, double-blind, placebo-controlled Phase 2b trial for GH001 in TRD (GH001-TRD-201), this trial may ultimately fail to show the desired safety profile, which could have a material adverse impact on our business, operations and financial results. Any such results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial, and in the case of the open-label extension phase of our Phase 2b trial for GH001 in TRD (GH001-TRD-201), also completing an initial safety analysis. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary or top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data